Cargando…
Cardiovascular Magnetic Resonance in the Oncology Patient
Patients with or receiving potentially cardiotoxic treatment for cancer are susceptible to developing decrements in left ventricular mass, diastolic function, or systolic function. They may also experience valvular heart disease, pericardial disease, or intracardiac masses. Cardiovascular magnetic r...
Autores principales: | Jordan, Jennifer H., Todd, Ryan M., Vasu, Sujethra, Hundley, W. Gregory |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242266/ https://www.ncbi.nlm.nih.gov/pubmed/30092971 http://dx.doi.org/10.1016/j.jcmg.2018.06.004 |
Ejemplares similares
-
Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance
por: Vasu, Sujethra, et al.
Publicado: (2013) -
Dispersion of hyperenhancement in late gadolinium enhancement cardiovascular magnetic resonance measured with Moran's I is associated with a decrement in LVEF 6 months after cardiotoxic chemotherapy
por: Jordan, Jennifer H, et al.
Publicado: (2013) -
Asymptomatic myocardial ischemia forecasts adverse events in cardiovascular magnetic resonance dobutamine stress testing of high-risk middle-aged and elderly individuals
por: Stacey, R. Brandon, et al.
Publicado: (2018) -
Dobutamine induced changes in aortic stiffness: influence of obesity in middle aged and elderly individuals with hypertension, diabetes or coronary artery disease
por: Vasu, Sujethra, et al.
Publicado: (2013) -
The 20 year evolution of dobutamine stress cardiovascular magnetic resonance
por: Charoenpanichkit, Charaslak, et al.
Publicado: (2010)